NCT06860711View on ClinicalTrials.gov

Safety of Short-course of NSAIDs in Pediatric Patients With CKD

PHASE4RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 22, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Chronic Kidney DiseasePediatric Urology
Interventions
DRUG

NSAIDs

IV formulation: ketorolac 0.5mg/kg/dose, 15mg maximum, no more than 8 doses total PO formulation: ibuprofen suspension 10mg/kg/dose, 400mg maximum Total duration (IV + PO) will not exceed 5 days.

DRUG

Placebo

IV or PO medication, compounded to have similar look, consistency and taste to the corresponding medications

Trial Locations (1)

80045

RECRUITING

Children's Hospital Colorado, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER